Home Sectors Healthcare Valuation Now: Inogen Inc (NASDAQ: INGN)

Valuation Now: Inogen Inc (NASDAQ: INGN)


Inogen Inc is in the healthcare sector and trades as part of the medical devices industry. The company CEO is Scott Wilkinson. Inogen Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Previous Intraday Trading Performance:

The INGN stock showed a previous change of 0.42% with an open at 67.45 and a close of 67.67. It reached an intraday high of 68.28 and a low of 64.96.

SeekingAlpha:  Can Reduced Expectations And A New Product Rebuild Inogen’s Premium?


The stock has a market cap of $1.5b with 21.9m shares outstanding, of which the float is 21.7m shares. Trading volume reached 497,213 shares compared to its average volume of 707,741 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Inogen Inc shares returned 2.16% and in the past 30 trading days it returned -23.20%. Over three months, it changed -29.72%. In one year it has changed -62.70% and within that year its 52-week high was 287.79 and its 52-week low was 62.32. INGN stock is 8.59% above its 52 Week Low.

Our calculations show a 200 day moving average of 142.53 and a 50 day moving average of 77.07. Currently INGN stock is trading -52.52% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Can Reduced Expectations And A New Product Rebuild Inogen’s Premium?


The last annual fiscal EPS for the company was reported at 2.3 that ended on 31st of December 2018, which according to the previous close, that is a PE of 29.42. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.30. The TTM EPS is 2.30, which comes to a TTM PE of 29.42. Historically, the PE high was 302.90 and the PE low was 29.42. INGN stock has set a new PE low record!

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/07/2019): 0.24
4thQtr of 2018 (Reported on 02/26/2019): 0.44
3rdQtr of 2018 (Reported on 11/06/2018): 0.73
2ndQtr of 2018 (Reported on 08/07/2018): 0.65
1stQtr of 2018 (Reported on 04/30/2018): 0.48

Base on our calculations, the intrinsic value per share is 99.17, which means it is possibly undervalued and has a margin of safety of 31.76%.

Indicators to Watch:

The current calculated beta is 1.49.

PR Newswire:  Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 16.98%, return on assets is 14.03%, profit margin is 12.63%, price-to-sales is 4.00 and price-to-book is 4.59.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 4  :Past Performance Score
 6  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.